Allspring中小型核心主动型ETF ASCE 深 沪
已收盘 07-02 16:00:00 美东时间
34.17
-0.520
-1.50%
华盛通- 最 高34.96
- 今 开34.96
- 成交量 1.03万股
- 最 低 33.86
- 昨 收 34.69
- 总市值 1.00亿
- 52周最高 35.22
- 市盈率 静 --
- 换手率 0.35%
- 52周最低 24.0619
- 委 比 0.00%
- 总股本 294.00万
- 历史最高 35.22
- 量 比 0.19
- 振 幅 3.17%
- 历史最低 24.0619
- 每 手 1
- 风险率 2.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Amentum rises after winning NASA’S COSMOS Contract
Shares of Amentum (AMTM) rose nearly 8% premarket on Tuesday after the company said it has been awarded NASA’s Consolidated Spaceflight Mission Operations and Systems (COSMOS) contract. The award com...
06-30 20:42
Gilead's Trodelvy gains new breast cancer indications
The US FDA has approved Gilead Sciences' (GILD) Trodelvy (sacituzumab govitecan) as a first-line treatment as monotherapy and in combination with Merck's (MRK) Keytruda (pembrolizumab) for triple-nega...
06-25 04:37
EU approves Gilead Trodelvy as first-line treatment for metastatic triple-negative breast cancer patients ineligible for PD-(L)1 inhibitors
EU approves Gilead Trodelvy as first-line treatment for metastatic triple-negative breast cancer patients ineligible for PD-(L)1 inhibitors European Commission granted marketing authorization for Gilead’s Trodelvy as first-line monotherapy in metastatic TNBC for patients not eligible for PD-1/PD-L1
06-23 19:45
Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics
The Supreme Court unanimously sided with generic drugmaker Hikma (HKMPF) and against Amarin Corp. (AMRN) in a case dealing with narrower labels for generic products compared to their brand equivalents...
06-05 01:46
Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027
Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced a trial in
05-22 05:38
HLS Therapeutics Q1 2026 Earnings Call Transcript
On Friday, HLS Therapeutics (TSX:HLS) discussed first-quarter financial results...
05-15 23:31
Merck reports 5-year KEYNOTE-942 data for mRNA-4157 plus Keytruda in melanoma
Merck reports 5-year KEYNOTE-942 data for mRNA-4157 plus Keytruda in melanoma Merck flagged late-stage updates across its oncology portfolio scheduled for presentation at ASCO 2026, led by long-term follow-up from KEYNOTE-942 testing individualized neoantigen therapy intismeran autogene with Keytrud
05-12 18:45
ADMA Biologics Earnings Call: ASCENIV Fuels Profits
ADMA Biologics Inc (($ADMA)) has held its Q1 earnings call. Read on for the mai...
05-08 10:24
ADMA Biologics declines 17% after lowering FY26 outlook, withdrawing long-term guidance
ADMA Biologics (ADMA) declined more than 17% on Thursday after the company lowered its full-year outlook and withdrew its long-term guidance, citing “uncertainty in the competitive landscape”. The sto...
05-08 00:17
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang
BUZZ-Street View: Azure gains keep Microsoft bulls onside despite capex overhang ** Microsoft MSFT.O said on Weds that Azure cloud revenue would beat Wall St forecasts and announced $190 bln in capital spending for 2026, exceeding expectations ** Shares down 1.1% premarket AZURE ASCENDS ** Citigroup
04-30 16:24
